Inflammation and Immunology
In September 2015 Evotec announced that it has signed an agreement on a four-year research collaboration with Pfizer Inc. in the field of tissue fibrosis.
Under the terms of this licence and collaboration agreement, scientists at Evotec and Pfizer explore potential novel mechanisms as targeted anti-fibrotics in multi-organ fibrosis. Evotec contribute its drug discovery platform whereas Pfizer provide key technologies and industrial scope as well as pharmaceutical development and marketing expertise.
Financial terms of the collaboration include an upfront payment and potential milestone payments from Pfizer based on the achievement of specific development and sales milestones.
Second Genome/ SGM-1019
In March 2015, Evotec and Second Genome, Inc. announced a collaboration in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. The collaboration comprises the identification and optimisation of novel compounds as well as licence agreements for already existing assets developed by Evotec. Second Genome's unique approach to identify and modulate microbiome-mediated pathways will be further enhanced by the use and the results of Evotec's integrated drug discovery platform.
As part of the collaboration, Second Genome and Evotec work together to screen microbiome-mediated targets of interest identified by the Second Genome microbiome discovery platform with Evotec's technology platform, chemical libraries and other pre-clinical capabilities. The agreement between Evotec and Second Genome triggered an undisclosed upfront payment. Evotec is also eligible for pre-clinical, clinical and regulatory milestones as well as royalty payments related to commercialisation.
In January 2019, Evotec announced that Second Genome had proceeded into a clinical Phase II trial for nonalcoholic steatohepatitis (NASH) with its lead programme SGM-1019, triggering a $ 2 m success payment to Evotec. The Phase II trial of SGM-1019 has been initiated following the completion of two successful Phase I trials.
CONBA Pharmaceutical/ EVT401
In May 2012, Evotec and CONBA Pharmaceutical Co., Ltd. announced the grant of a development and marketing licence on EVT401, a selective, small molecule P2X7 antagonist, for human indications with exception of ophthalmological, chronic obstructive pulmonary disease (“COPD”) and endometriosis in China.
Evotec received a small upfront payment and is eligible for development and commercial milestone payments in excess of € 60 m and tiered double-digit royalties on net sales. The agreement grants CONBA exclusive rights to develop and commercialise the compound for the Chinese market. Evotec will have the right to reference clinical data produced by CONBA Pharmaceutical to support potential further development of EVT401 in other territories.
P2X7 receptor antagonism may provide a novel approach for the treatment of inflammatory conditions. Evotec has completed the first Phase I, single dose study of EVT 401 in 2010. CONBA will initiate further clinical trials with EVT401 in China in inflammatory diseases. In July 2013, CONBA received green light from the Chinese government to continue their studies on the EVT401 programme.